US Stock Insider Trading | Solid Biosciences disclosed 6 insider transactions on February 18

2026-02-20 18:14:20

On February 18, 2026, Solid Biosciences (SLDB) disclosed six insider trading transactions. Director Cumbo Alexander sold 16,600 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 18, 2026	Executive	Hanrahan Jessie	February 18, 2026	Sell	4,134	5.82	$24,100
February 18, 2026	Executive	Tan Kevin	February 18, 2026	Sell	5,404	5.82	$31,500
February 18, 2026	Executive	Brooks Gabriel	February 18, 2026	Buy	0	5.82	0.0000
February 18, 2026	Executive	Howton David T	February 18, 2026	Sell	7,469	5.82	$43,500
February 18, 2026	Director	Ganot Ilan	February 18, 2026	Sell	2,658	5.82	$15,500
February 18, 2026	Executive	Herzich Paul	February 18, 2026	Sell	3,616	5.82	$21,100
February 18, 2026	Director	Cumbo Alexander	February 18, 2026	Sell	16,600	5.82	$96,900
February 6, 2026	Executive	Herzich Paul	February 4, 2026	Sell	10,900	6.44	$70,200
February 6, 2026	Executive	Hanrahan Jessie	February 4, 2026	Sell	12,300	6.44	$79,500
February 6, 2026	Executive	Brooks Gabriel	February 4, 2026	Sell	12,600	6.44	$81,300

[Company Profile]

Solid Biosciences Inc., formerly known as SOLID Ventures Management, LLC, was established in March 2013 as a Delaware limited liability company. The company is a life sciences firm focused on advancing current and future gene therapy candidate portfolios, collectively referred to as candidates, including SGT-003 for Duchenne muscular dystrophy, or Duchenne, SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), and additional assets for cardiac and other diseases at various stages of development with different investment levels. The company is developing a diversified pipeline targeting rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-centered and founded by individuals directly affected by Duchenne, the company’s mission is to improve the daily lives of patients suffering from these devastating diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes